Medical Foods for Inborn Errors of Metabolism Market to Grow at a CAGR of 11.2% to reach US$ 5,768.79 Million from 2020 to 2027

The medical foods for inborn errors of metabolism market was valued at US$ 2,507.80 million in 2019 and it is projected to reach US$ 5,768.79 million in 2027; it is expected to grow at a CAGR of 11.2% from 2020 to 2027.

Medical food refers to the specialized kind of food formulated to be consumed under physician supervision and intended for specific dietary management of a particular disease or condition. These medical conditions usually have distinctive nutritional requirements based on scientific and recognized principles that are established by medical evaluation. The medical food differs from drugs; however they are intended for consumption under the medical supervision as a primary intervention. When infants are identified with inborn errors of metabolism, they are usually prescribed a special diet suitable to their particular condition that must be followed for the lifetime. The growth of the global medical foods for inborn errors of metabolism market is attributed to the increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements. However, limitations associated to medical foods for inborn errors of metabolism is the major factor hindering the market growth.

The global medical foods for inborn errors of metabolism market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Global Medical Foods for Inborn Errors of Metabolism Market

Get more information on this report : Request Free Sample PDF

Market Insights

Growing Preference toward Dietary Supplements to Drive Global Medical Foods for Inborn Errors of Metabolism Market Growth

The rates for consumption of nutraceutical supplements and prescribed medical food are increasing over enzyme-based therapeutic medicines. The increasing costs of healthcare and rising preference of consumers toward simple and effective remedies for disease management are likely to be responsible for the changing lineage from medicines toward medical supplements and nutritional foods. Medical food refers to a category of products that are used in dietary management of various diseases including inborn errors of metabolism that contains specific nutrients to fulfill the nutrient requirements for patients suffering from particular conditions.

The US Food and Drug Administration (FDA) have categorized medical food under four major categories formulas for metabolic disorders, complete nutritional products, nutritionally incomplete products, and oral rehydration solutions. 

The medical foods are easy to be accessed as they do not require a prescription but are necessarily consumed under a medical supervision. In case of inborn errors of metabolism, medical foods are used as treatment options, and the products available in the market are regulated under authoritative and regulatory food and diet supplement statuses. The nutritional treatment for inborn errors of metabolism provides between 85% and 90% of nutritional requirement for a person suffering from a particular inherited disorder. Moreover, there are almost negligible side effects of these supplements, making them ideal for consumption for patients of all age groups. In recent years, the private medical insurers in the US and a few other countries are also offering reimbursement programs for the consumption of certain medical foods. Thus, the rising adoption of medical food and nutrient supplements is expected to foster the market growth over the years to come.

Product -Based Insights

In terms of product type, the global medical foods for inborn errors of metabolism market is segmented into amino acids, glytactin with GMP, amino acid-modified infant formula with iron, low calcium/vitamin-D infant formula with iron, low protein food and others. In 2019, the amino acid segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.

Global Medical Foods for Inborn Errors of Metabolism Market, by Product– 2019 and 2027

Get more information on this report : Request Free Sample PDF

Age group -Based Insights

In terms of age group, the global medical foods for inborn errors of metabolism market is segmented into infants, weaning, adolescents and adults. In 2019, the infants segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.

Disease -Based Insights

Based on disease, the global medical foods for inborn errors of metabolism market is segmented into phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystonuria, urea cycle disorders, methylmelonic academia, organic acidureas, propionic academia, isovaleric academia, disorders of leucine metabolism, glutaric academia type-1, renal disease, tyrosinemia types I and II and others. The phenylketonuria segment held the largest market share in 2019. However, the glutaric academia type-1 segment is expected to grow at the fastest rate during the coming years.

Forms -Based Insights

Based on forms, the global medical foods for inborn errors of metabolism market is segmented into powder, liquids, gels, and others. The powder segment held the largest market share in 2019. Also, the same segment is estimated to grow at the highest CAGR during the forecast period.

Packaging-Based Insights

In terms of packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packet, bottle, and others. The can segment held the largest share of the market in 2019. However, the packets segment is expected to grow at the highest CAGR during the forecast period.

Distribution Channel -Based Insights

In terms of distribution channel, the global medical foods for inborn errors of metabolism market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, drug stores and others. The retail pharmacies segment held the largest share of the market in 2019. Also, the same segment is estimated to grow at the fastest rate during the forecast period.

Strategic Insights

Report Coverage - Medical Foods for Inborn Errors of Metabolism Market

Report Coverage	Details
Market Size Value in	US$ 2,507.80 Million in 2019
Market Size Value by	US$ 5,768.79 Million by 2027
Growth rate	CAGR of 11.2% from 2020-2027
Forecast Period	2020-2027
Base Year	2020
No. of Pages	243
No. of Tables	147
No. of Charts & Figures	98
Historical data available	Yes
Segments covered	Product ; Age group ; Disease ; Forms ; Packaging ; Distribution Channel ; and Geography
Regional scope	North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scope	US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available	Get Free Sample PDF

The global medical foods for inborn errors of metabolism market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Global Medical Foods for Inborn Errors of Metabolism Market – by Product

• Amino Acid
• Glytactin with GMP
• Amino Acid-Modified Infant Formula With Iron
• Low-Calcium/Vitamin D-free Infant Formula With Iron
• Low Protein Food
• Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Age Group

• Infants
• Weaning
• Adolescents
• Adults    

Global Medical Foods for Inborn Errors of Metabolism Market – by Disease

• Phenylketonuria(PKU)
• Maple Syrup Urine Disease(MSUD)
• Homocystinuria
• Urea Cycle Disorders
• Methylmalonic Acidemia
• Organic Acidurias
• Propionic Acidemia
• Isovaleric aciDemia
• Disorders of Leucine Metabolism
• Glutaric Acidemia Type I
• Renal Disease
• Tyrosinemia Types I and II
• Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Forms

• Powder
• Liquid
• Gels
• Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Packaging

• Can
• Jar
• Packets
• Bottle
• Others 

Global Medical Foods for Inborn Errors of Metabolism Market – by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Drugstores
• Others

Global Medical Foods for Inborn Errors of Metabolism Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South America and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Nestlé Health Science
• Abbott
• Reckitt Benckiser Group Plc
• Ajinomoto Cambrooke, Inc.
• Solace Nutrition
• Primus Pharmaceuticals, Inc.
• BioMarin Pharmaceutical
• Danone SA
• Galen Limited
• PKU-MDmil